Retinitis Pigmentosa Treatment Market Size in the 7MM was valued ~USD 500 Million in 2023, It is expected to grow by 2034 and estimates DelveInsight

Retinitis Pigmentosa Treatment Market Size, Drugs, Companies

Retinitis Pigmentosa Market Infographic

1. Key Insights
2. Report Introduction
3. Executive Summary of Retinitis Pigmentosa (RP)
4. Retinitis Pigmentosa Market Overview at a Glance
4.1. Market Share by Therapies (%) Distribution of Retinitis Pigmentosa in 2020 in the 7MM
4.2. Market Share by Therapies (%) Distribution of Retinitis Pigmentosa in 2034 in the 7MM
5. Key Events
6. Epidemiology and Market Forecast Methodology
7. Retinitis Pigmentosa: Disease Background and Overview
7.1. Introduction
7.2. Signs and Symptoms
7.3. Causes of Retinitis Pigmentosa
7.4. Classification of Retinitis Pigmentosa
7.5. Pathophysiology
7.6. Diagnosis of Retinitis Pigmentosa
7.6.1. Diagnostic Tests
7.6.2. Differential Diagnosis of Retinitis Pigmentosa
7.6.3. Diagnostic Guidelines
7.6.3.1. American Academy of Ophthalmology: Guidelines on Clinical Assessment of Patients With Inherited Retinal Degenerations &ndash; 2022
7.7. Prognosis
8. Treatment of Retinitis Pigmentosa
8.1. Future Treatment Modalities
8.2. General Recommendations for RP Treatment
8.3. Treatment Guidelines for Retinitis Pigmentosa
8.3.1. Treatment Guidelines Yoshimune et al. (2017)
8.3.2. Treatment Recommendations as suggested by Gallemore et al. (2017)
9.&nbsp;Retinitis Pigmentosa Epidemiology and Patient Population
9.1. Key Findings
9.2. Assumptions and Rationale
9.3. Total Prevalent Cases of Retinitis Pigmentosa in the 7MM
9.4. The United States
9.4.1. Total Prevalent Cases of Retinitis Pigmentosa in the US
9.4.2. Gender-specific Cases of Retinitis Pigmentosa in the United States
9.4.3. Type-specific Cases of Retinitis Pigmentosa in the United States
9.4.4. Sub-type Specific Cases of Syndromic and Systemic Retinitis Pigmentosa in the United States
9.4.5. Sub-type Specific Cases of Non-syndromic Retinitis Pigmentosa in the United States
9.5. EU4 and the UK
9.5.1. Total Prevalent Cases of Retinitis Pigmentosa in EU4 and the UK
9.5.2. Gender-specific Cases of Retinitis Pigmentosa in EU4 and the UK
9.5.3. Type-specific Cases of Retinitis Pigmentosa in EU4 and the UK
9.5.4. Sub-type Specific Cases of Syndromic and Systemic Retinitis Pigmentosa in EU4 and the UK
9.5.5. Sub-type Specific Cases of Non-syndromic Retinitis Pigmentosa in EU4 and the UK
9.6. Japan
9.6.1. Total Prevalent Cases of Retinitis Pigmentosa in Japan
9.6.2. Gender-specific Cases of Retinitis Pigmentosa in Japan
9.6.3. Type-specific Cases of Retinitis Pigmentosa in Japan
9.6.4. Sub-type Specific Cases of Syndromic and Systemic Retinitis Pigmentosa in Japan
9.6.5. Sub-type Specific Cases of Non-syndromic Retinitis Pigmentosa in Japan
10. Patient Journey
10.1. Description
11.&nbsp;Retinitis Pigmentosa Marketed Drugs
11.1. LUXTURNA: Sparks Therapeutics (Roche)/Novartis
11.1.1. Product Description
11.1.2. Regulatory Milestones
11.1.3. Others Developmental Activities
11.1.4. Clinical Developmental
11.1.4.1. Clinical Trial Information
11.1.5. Safety and Efficacy
11.1.6. Product Profile
12.&nbsp;Retinitis Pigmentosa Emerging Drugs
12.1. Key Competitors
12.2. Botaretigene sparoparvovec: Johnson &amp; Johnson Innovative Medicine /MeiraGTx
12.2.1. Product Description
12.2.2. Other Developmental Activities
12.2.3. Clinical Developmental Activities
12.2.4. Safety and Efficacy
12.3. AGTC-501: Beacon Therapeutics
12.3.1. Product Description
12.3.2. Other Development Activities
12.3.3. Clinical Developmental Activities
12.3.4. Safety and Efficacy
12.4. MCO-010: Nanoscope Therapeutics
12.4.1. Product Description
12.4.2. Other Developmental Activities
12.4.3. Clinical Developmental Activities
12.4.4. Safety and Efficacy
12.5. GS030: Gensight Biologics
12.5.1. Product Description
12.5.2. Other Developmental Activities
12.5.3. Clinical Developmental Activities
12.5.4. Safety and Efficacy
12.6. 4D 125: 4D Molecular Therapeutics
12.6.1. Product Description
12.6.2. Other Developmental Activities
12.6.3. Clinical Developmental Activities
12.6.4. Safety and Efficacy
12.7. CTx PDE6B: Coave Therapeutics
12.7.1. Product Description
12.7.2. Other Developmental Activities
12.7.3. Clinical Developmental Activities
12.7.4. Safety and Efficacy
12.8. OCU 400: Ocugen
12.8.1. Product Description
12.8.2. Other Developmental Activities
12.8.3. Clinical Developmental Activities
12.8.4. Safety and Efficacy
12.9. BS01: Bionic Sight
12.9.1. Product Description
12.9.2. Clinical Developmental Activities
12.9.3. Safety and Efficacy
12.1. jCell: jCyte
12.10.1. Product Description
12.10.2. Other Developmental Activities
12.10.3. Clinical Developmental Activities
12.10.4. Safety and Efficacy
12.11. EA-2353: Endogena Therapeutics
12.11.1. Product Description
12.11.2. Other Developmental Activities
12.11.3. Clinical Developmental Activities
12.12. Ultevursen: ProQR Therapeutics
12.12.1. Product Description
12.12.2. Other Developmental Activities
12.12.3. Clinical Developmental Activities
12.12.4. Safety and Efficacy
12.13. ADX 2191: Aldeyra Therapeutics
12.13.1. Product Description
12.13.2. Other Developmental Activities
12.13.3. Clinical Developmental Activities
12.13.4. Safety and Efficacy
13. Retinitis Pigmentosa: Market Analysis
13.1. Key Findings
13.2. Market Outlook
13.3. Conjoint Analysis
13.4. Key Market Forecast Assumptions
13.5. Total Market Size of Retinitis Pigmentosa in the 7MM
13.6. United States Market Size
13.6.1. Total Market Size of Retinitis Pigmentosa in the United States
13.6.2. Market Size of Retinitis Pigmentosa by Therapies in the United States
13.7. EU4 and the UK Market Size
13.7.1. Total Market Size of Retinitis Pigmentosa in EU4 and the UK
13.7.2. Market Size of Retinitis Pigmentosa by Therapies in EU4 and the UK
13.8. Japan Market Size
13.8.1. Total Market Size of Retinitis Pigmentosa in Japan
13.8.2. Market Size of Retinitis Pigmentosa by Therapies in Japan
14.&nbsp;Retinitis Pigmentosa Unmet Needs
15.&nbsp;Retinitis Pigmentosa SWOT Analysis
16.&nbsp;Retinitis Pigmentosa KOL Views
17.&nbsp;Retinitis Pigmentosa Market Access and Reimbursement
17.1. United States
17.1.1. Centre for Medicare and Medicaid Services (CMS)
17.2. EU4 and the UK
17.2.1. Germany
17.2.2. France
17.2.3. Italy
17.2.4. Spain
17.2.5. United Kingdom
17.3. Japan
17.3.1. MHLW
17.4. Market Access and Reimbursement of Retinitis Pigmentosa
18. Appendix
18.1. Bibliography
18.2. Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
 
21. About DelveInsight

Retinitis Pigmentosa Market

Retinitis Pigmentosa Market Insight, Epidemiology And Market Forecast - 2034

DelveInsight's Retinitis Pigmentosa Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of the Retinitis Pigmentosa, historical and forecasted epidemiology as well as the Retinitis Pigmentosa market trends in 7MM.